Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018
Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
A 52-year-old woman with a 3 weeks of progressive gait ataxia and dysarthria
Neurol 90:e985-e989, Ly, C.,et al, 2018
Fulminant Encephalopathy with Unusual Brain Imaging in Disulfiram Toxicity
Neurol 90:518-519, Peddawad, D.,et al, 2018
A 12-year-old girl with headache and change in mental status
Neurol 90:524-529, Patel, P.,et al, 2018
Primary Thrombectomy in tPA (Tissue-Type Plasminogen Activator) Eligible Stroke Patients with Proximal Intracranial Occlusions
Stroke 49:265-269, Fischer, U.,et al, 2018
Clinicopathologic Conference, Human Herpesvirus 6-Related Meningoencephalitis
NEJM 378:659-669, Case 5-2018, 2018
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
A 56-year-old woman with acute vertigo and diplopia
Neurol 90:748-752, Sharma, R.,et al, 2018
Toxidrome Recognition in Chemical - Weapons Attacks
NEJM 378:1611-1620, Ciottone, G.R., 2018
Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke
NEJM 378:1573-1582, Campbell, B.C.V.,et al, 2018
Automated DWI analysis can identify patients within the thrombolysis time window of 4.5 hours
Neurol 90:e1570-e1577, Wouters, A.,et al, 2018
Acute acalculous cholecystitis
Neurol 90:e1548-e1552, Croteau, D.,et al, 2018
Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants with Serotonin Syndrome
JAMA Neurol 75:566-572, Orlova, Y.,et al, 2018
A 77-year-old man presenting with episodic expressive aphasia
Neurol 90:e1822-e1826, Shanklin, A.,et al, 2018
Time to Decision and Treatment with tPA (Tissue-Type Plasminogen Activator) Using Telemedicine Versus an Onboard Neurologist on a Mobile Stroke Unit
Stroke 49:1528-1530, Bowry, R.,et al, 2018
Magnetic Resonance Imaging Selection for Endovascular Stroke Therapy
Stroke 49:1402-1406, Simonsen, C.Z.,et al, 2018
Diagnosis and Management of Active Intracranial Atherosclerotic Disease
Stroke 49:e221-e223, Narwal, P.,et al, 2018
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset
NEJM 379:611-622, 682, Thomalla, G.,et al, 2018
Intravenous Thrombolysis in Unwitnessed Stroke Onset: MR WITNESS Trial Results
Ann Neurol 83:980-993, Schwamm, L.H.,et al, 2018
Autoimmune Pancerebellitis Associated with Pembrolizumab Therapy
Neurol 91:91-93, Vitt, J.R.,et al, 2018
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Acute Viral Encephalitis
NEJM 379:357-366, Tyler,K.L., 2018
Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients with Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke
Stroke 49:2237-2240, Jin, C.,et al, 2018
Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer
Neurol 91:e985-e994, Touat, M.,et al, 2018
Interventions for Improving Modifiable Risk Factor Control in the Secondary Prevention of Stroke
Stroke 49:e301-e302, Bridgwood, B.,et al, 2018
Mechanical Thrombectomy Outcomes with or without Intravenous Thrombolysis
Stroke 49:2383-2390, Gariel, F.,et al, 2018
Endovascular Stroke Therapy in the Late Time Window
Stroke 49:2559-2561, Schellinger, P.D. & Demaerschalk, B.M., 2018
Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis
Neurol 91:622-624, Midaglia, L.,et al, 2018
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Selenium Toxicity Associated with Reversible Leukoencephalopathy and Cortical Blindness
JAMA Neurol 75:1282-1283, Rae, W.,et al, 2018
Use of Newer Disease-Modifying Therapies in Pediatric Multiple Sclerosis in the US
Neurol 91:e1778-e1787, Krysko, K.M.,et al, 2018
Preventive Migraine Drug Approved
JAMA 320:1746, , 2018
Hearing and Vision Loss in an Older Man
JAMA Neurol 75:1439-1440, Ho, V.M.,et al, 2018
Surviving Cerebral Malaria
Neurol 91:978-979, Wijdicks, E.F.M. & Park, J.G., 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Implications of the WAKE-UP Trial
Stroke 49:3115-3117, Silver, B. & Arnold, M., 2018
Progressive Gait Difficulty and Incontinence in a 40-year-old Man with HIV
Neurol 91:1065-1070, Silverman, A.,et al, 2018
Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018
Rapid Progression of Reversible Cognitive Impairment in an 80-year-old Man
Neurol 91:1109-1113, Bouthour, W.,et al, 2018
Elsberg Syndrome
Neurol Neuroimmunol Neuroinflamm 4:e355-e362, Savoldi, F.,et al, 2017
Intracranial Meningeal Enhancement Characterization
Rev Colomb Radiol 28:4709-4716, Mera, J.L.C.,et al, 2017
Clinicopathologic Conference, Paroxysmal Nocturnal Hemoglobinuria
NEJM 377:2581-2590, Case 40-2017, 2017
Disseminated Aspergillosis in an HIV-positive Cannabis user taking steroid treatment
Lancet Infect Dis 17:882, Salam, A.P. & Pozniak, A.L., 2017
Increasing Prevalence of Vascular Risk Factors in Patients with Stroke
Neurol 89:1985-1994, Otite, F.O.,et al, 2017
Clinical Pathologic Conference, West Nile Virus Encephalitis
NEJM 377:1878-1886, Case 34-2017, 2017
Infliximab for the Treatment of CNS Sarcoidosis
Neurol 89:2092-2100, Gelfand, J.M.,et al, 2017
Clinical Imaging Factors Associated with Infarct Progression in Patients with Ischemic Stroke During Transfer for Mechanical Thrombectomy
JAMA Neurol 74:1361-1367,1298, Boulouis, G.,et al, 2017
An 82-year-old man with Worsening Gait
Neurol 89:e246-e252, Chew, S.,et al, 2017
Treatment and Outcome of Hemorrhagic Transformation after Intravenous Alteplase in Acute Ischemic Stroke
Stroke 48:e343-e361, Yaghi, S.,et al, 2017